First Stereoselective Synthesis of Penicilllenol A1 via Novel O- to C-Acyl Rearrangement of O-Acyltetramic Acid

著者	Yoda Hidemi, Sengoku Tetsuya, Wierzejska Jolanta, Takahashi Masaki
journal or publication title	Synlett
volume	2010
number	19
page range	2944-2946
year	2010
出版者	Thieme
権利	(C) Georg Thieme Verlag KG Stuttgart New York. All rights reserved.
URL	http://hdl.handle.net/10297/6543

doi: 10.1055/s-0030-1259045

First stereoselective synthesis of penicillenol A₁ via novel *O*- to *C*-acyl rearrangement of *O*-acyltetramic acid

Tetsuya Sengoku, Jolanta Wierzejska, Masaki Takahashi, and Hidemi Yoda *

Department of Materials Science, Faculty of Engineering, Shizuoka University, 3-5-1 Johoku, Naka-ku, Hamamatsu, Shizuoka 432-8561, Japan

Fax: +81(53)4781150

E-mail: tchyoda@ipc.shizuoka.ac.jp

The first stereoselective synthesis of penicillenol A₁ has been accomplished in 9 steps from L-threonine. The 3-acyltetramic acid core of penicillenol A₁ was constructed by successful *O*- to *C*-acyl rearrangement.

Key words: stereoselective synthesis, penicillenol A₁, *O*- to *C*-acyl rearrangement, 4-*O*-acyltetramic acid, 3-acyltetramic acid

Penicillens A₁ and A₂ are tetramic acid derivatives recently isolated from the culture broth of a fungus *Penicillium* sp., an endophytic fungus associated with *Aegiceras corniculatum* (Figure 1).¹ Penicillenol A₁ (1) has been identified as a potent cytotoxic agent (HL-60, IC₅₀ = 0.76 μM), displaying much higher activity than penicillenol A₂ (2). Although their planar structures and the absolute stereochemistry of the chiral center at C5 were elucidated by the analysis of NMR and CD spectra, absolute configurations of the C6 and C9 stereocenters remained unspecified. Here we report an efficient synthesis of penicillenol A₁ in an effort to establish the absolute configurations.

Figure 1 Structures of penicillens A₁ and A₂.

Our synthetic plan for penicillenol A₁ is outlined in Figure 2. We expected that natural penicillenol A₁ would have (6*R*)-configuration, considering that the tetramic acid moiety is biosynthetically derived from L-threonine.^{1,2} Accordingly, we decided to synthesize two possible diastereomers of (6*R*)-penicillenol A₁ by employing acylation of tetramic acid **3** with chiral carboxylic acid **4**.

Figure 2 Retrosynthetic analysis of (6*R*)-penicillenol A₁

The synthesis commenced with the preparation of the TBS-protected tetramic acid **3** (Scheme 1). Condensation of L-threonine derivative **5**³ with

Meldrum's acid in the presence of *N,N'*-dicyclohexylcarbodiimide (DCC) and 4-(dimethylamino)pyridine (DMAP), followed by the cyclization with concomitant loss of carbon dioxide and acetone provided *N*-Cbz derivative of **3**.⁴ The Cbz group was removed under hydrogenation conditions to furnish desired **3** in 38% yield (three steps) from **5**.

Scheme 1 Reagents and conditions: (a) (i) Meldrum's acid, DCC, DMAP, CH₂Cl₂, 0 °C; (ii) EtOAc, reflux; (iii) H₂, Pd/C, EtOAc, 38% (three steps); (b) (*R*)-**4**, DCC, DMAP, CH₂Cl₂, then Et₃N, trace; (c) (*R*)-**4**, *i*-BuOCOCl, *N*-methylmorpholine, Et₂O, 0 °C, then, 3, Et₃N, rt, 95%; (d) (i) NaHMDS, MeI, THF, -40 °C, 78%; (ii) 2% HCl/MeOH, 0 °C, 78%.

With tetramic acid **3** in hand, we turned our attention to the preparation of the C3-acylated target product obtained from the reaction with (*R*)-2-methyloctanoic acid ((*R*)-**4**)⁵ according to the reported reaction conditions.⁶ Although initial conversion from **3** into 4-*O*-acyltetramic acid ((*R*)-**7**) was achieved by the reaction with (*R*)-**4** in the presence of DCC and DMAP, *O*- to *C*-acyl rearrangement with Et₃N proceeded slowly to give only a trace amount of desired (6*R*,9*R*)-**6**. This low reactivity would be attributed to the steric hindrance around a carboxyl group.⁷ Therefore, we next attempted a stepwise approach that uses 4-*O*-acyltetramic acid (*R*)-**7** prepared in 95% yield from the *O*-acylation of **3** with the mixed anhydride of (*R*)-**4** and isobutyl formate.

The results of *O*- to *C*-acyl rearrangement with (*R*)-**7** are summarized in Table 1. When the 4-*O*-acyl intermediate (*R*)-**7** was treated with DMAP and Et₃N, only a trace amount of the 3-acyltetramic acid (6*R*,9*R*)-**6** was obtained (entry 1). No significant change in conversion was observed at a higher temperature (entry 2), whereas a dramatic improvement was observed in the reaction with calcium chloride to afford desired (6*R*,9*R*)-**6** in 65%

isolated yield after separation of a trace amount of C5-isomerized product by silica gel column chromatography (entry 3). It is worth noting that the acyl rearrangement failed to give any desired compound in the absence of DMAP (entry 4), and, on the one hand, the reaction worked well without Et₃N to give (6*R*,9*R*)-**6** in enhanced 75% yield after chromatographic purification (entry 5). These results

Table 1 Acyl rearrangement of (*R*)-**7** to (6*R*,9*R*)-**6**.

Entry	DMAP (equiv)	Et ₃ N (equiv)	CaCl ₂ (equiv)	Solvent	Temp. (°C)	Time (h)	Yield (%) ^a
1	0.3	1.2	-	CH ₂ Cl ₂	rt	96	trace
2	0.3	1.2	-	ClCH ₂ CH ₂ Cl	50	24	trace
3	0.3	1.2	1.5	CH ₂ Cl ₂	rt	6	65
4	-	1.2	1.5	CH ₂ Cl ₂	rt	12	0
5	1.5	-	1.5	CH ₂ Cl ₂	rt	4	75

^a Isolated yield of (6*R*,9*R*)-**6**

Having achieved the preparation of the 3-acyltetramic acid structure, we focused on the final steps of the synthesis. After considering the reaction conditions, *N*-methylation of amide was achieved by treating deprotonated (6*R*,9*R*)-**6** with excess amount of iodomethane at -40 °C. In the course of this reaction, no detectable epimerization of the C5 stereocenter was observed. Finally, removal of TBS protecting group was conducted under acidic conditions to complete the first stereoselective synthesis of (6*R*,9*R*)-penicillenol A₁ ((6*R*,9*R*)-**1**) in 16% overall yield from **5**.⁹

The synthesis of another diastereomer (6*R*,9*S*)-**1** was also performed in the same manner as for (6*R*,9*R*)-**1** (Scheme 2). Thus, 4-*O*-acyltetramic acid (*S*)-**7** was synthesized by the acylation of **3** with (*S*)-**4** and converted to (6*R*,9*S*)-**1** in 36% yield (three steps).¹⁰

Scheme 2 Reagents and conditions: (a) (*S*)-**4**, *i*-BuOCOCl, *N*-methylmorpholine, Et₂O, 0 °C, then, **3**, Et₃N, rt, 95%; (b) (i) DMAP, CaCl₂, CH₂Cl₂, 60%; (ii) NaHMDS, MeI, THF, -40 °C, 82%; (iii) 2% HCl/MeOH, 0 °C, 74%.

As a matter of fact, ¹H NMR spectra of both synthetic penicillenols A₁ closely resembled those reported in the literature,¹ and detailed analysis of ¹³C NMR spectra of them indicated that ¹³C NMR spectra of (6*R*,9*S*)-**1** closely matched that of the natural product relative to that of (6*R*,9*R*)-**1**.^{11,12} However, the absolute value of optical rotation of (6*R*,9*S*)-**1** ([α]_D²⁹ -68.5 (*c* 0.618, MeOH)) was unexpectedly found to be inconsistent with that reported in the literature ([α]_D²⁹ -864.5 (*c* 0.155, MeOH)). From these results, it can be deduced that the natural sample may be contaminated with some impurities.¹³

In conclusion, we have achieved the first stereoselective syntheses of (6*R*,9*R*)- and (6*R*,9*S*)-penicillenol A₁ in 9 steps starting from L-threonine.

suggest that DMAP played a significant role in activation of the acyl moiety, which would be in close contact with the liberated tetramic acid via chelation of Ca²⁺ ions, promoting the rearrangement to give the desired product in good yields, although the exact mechanistic details of this process are still under investigation.⁸

As a consequence of the spectroscopic investigations, natural penicillenol A₁ has been found to have a (5*S*,6*R*,9*S*)-absolute configuration. Our synthetic approach involves novel acyl rearrangement mediated by calcium chloride. The syntheses of (6*S*)-derivatives of penicillenols A₁ and further investigations on the role of calcium chloride are now in progress.

Acknowledgment

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan and the Sasagawa Scientific Research Grant from The Japan Science Society.

References

- (1) Lin, Z.-J.; Lu, Z.-Y.; Zhu, T.-J.; Fang, Y.-C.; Gu, Q.-Q.; Zhu, W.-M. *Chem. Pharm. Bull.* **2008**, *56*, 217.
- (2) Probst, A.; Tamm, C. *Helv. Chim. Acta* **1981**, *64*, 2065.
- (3) Woulfe, S. R.; Miller, M. J. *J. Org. Chem.* **1986**, *51*, 3133.
- (4) (a) Jouin, P.; Castro, B.; Nisato, D. *J. Chem. Soc. Perkin Trans 1* **1987**, 1177. (b) Jiang, J.; Li, W.-R.; Przeslawski, R. M.; Joullie, M. M. *Tetrahedron Lett.* **1993**, *34*, 6075.
- (5) Kumagai, A.; Nagaoka, Y.; Obayashi, T.; Terashima, Y.; Tokuda, H.; Hara, Y.; Mukainaka, T.; Nishino, H.; Kuwajima, H.; Uesato, S. *Bioorg. Med. Chem.* **2003**, *11*, 5143.
- (6) Hori, K.; Arai, M.; Nomura, K.; Yoshii, E. *Chem. Pharm. Bull.* **1987**, *35*, 4368.
- (7) Under the same conditions, one-pot acylation between **3** and hexanoic acid gave 3-acyltetramic acid in 64% yield.

- (8) The addition of CaCl₂ also improved the yield in one-pot procedure. For example, the reaction of **3** with (*R*)-**4** in the presence of CaCl₂ afforded (6*R*,9*R*)-**6** in 59% yield, whereas a trace amount of (6*R*,9*R*)-**6** was obtained in the absence of CaCl₂ (see scheme 2).

(10) 4.7(1). Found: C, 64.55; H, 9.00; N, 4.31. (6*R*,9*S*)-Penicillenic Acid **1**, ((6*R*,9*S*)-**1**): $[\alpha]_D^{29}$ -68.5 (*c* 0.618, MeOH); IR (NaCl) 3425, 2956, 2928, 2857, 1708, 1642, 1610, 1486, 1460, 1378, 1342, 1089 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) 4.19 (dq, $J = 4.2, 6.3$ Hz, 1H, CH), 3.80 (d, $J = 4.2$ Hz, 1H, CH), 3.56 (m, 1H, CH), 2.99 (s, 3H, CH_3), 1.68 (m, 1H, CH_2), 1.47 (m, 1H, CH_2), 1.33-1.22 (m, 8H, CH_2), 1.18 (d, $J = 6.9$ Hz, 3H, CH_3), 1.14 (d, $J = 6.6$ Hz, 3H, CH_3), 0.87 (t, $J = 6.6$ Hz, 3H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) 194.7 (C), 192.8 (C), 174.1 (C), 100.9 (C), 68.5 (CH), 66.6 (CH), 36.4 (CH), 33.4 (CH_2), 31.5 (CH_2), 29.1 (CH_2), 27.1 (CH_3), 27.0 (CH_2), 22.4 (CH_2), 17.6 (CH_3), 17.0 (CH_3), 13.9 (CH_3); Anal. Calcd for $\text{C}_{16}\text{H}_{27}\text{NO}_4$: C, 64.62; H, 9.15; N, 4.71. Found: C, 64.86; H, 9.00; N, 4.31.

	C3	C4	C8	C9	C10
natural 1 ^a	100.9	194.6	192.6	36.3	33.4
(6 <i>R</i> ,9 <i>R</i>)- 1 ^b	101.2	195.0	192.9	36.3	33.9
$\Delta_{\delta 9R}^C$	+0.3	+0.4	+0.3	0	+0.5
(6 <i>R</i> ,9 <i>S</i>)- 1 ^b	100.9	194.7	192.8	36.4	33.4
$\Delta_{\delta 9S}^C$	0	+0.1	+0.2	+0.1	0

(12) ^a 150 MHz. ^b 75 MHz. ^c $\Delta_{\delta X} = \delta((6R,X)-1) - \delta(\text{natural } 1)$
¹H and ¹³C NMR spectra of (5*R*)-isomer of (6*R*,9*R*)-**1**, which was prepared by isomerization of **3** (DBU, toluene, 50 °C), was found to be quite similar to those of natural penicillenol A₂. This indicated that enantiomeric (5*S*,6*S*)-isomers should give NMR spectra similar to those of penicillenol A₂. Details of synthesis and characterization of (5*R*)-isomer of (6*R*,9*R*)-**1** will be presented in future work.

Template for *SYNLETT* and SYNTHESIS © Thieme Stuttgart · New York